New Report by BioTrends Research Group To Highlight The Launch Of SIMPONI® (golimumab)
Latest BioTrends Research Reports to Assess the Impact of the Withdrawal of RAPTIVA (efalizumab) on the Psoriasis Market
New BioTrends Research Report Reveals High Awareness of Takeda’s ULORIC (febuxostat) and a Sizeable Market Opportunity in the Chronic Gout Market
Takeda’s ULORIC® Achieves High Familiarity and Interest in First Month of Launch
BioTrends Prepares To Field ChartTrends™ Reports To Cover The Use Of Biologic Agents In Psoriasis And Rheumatoid Arthritis
Read more...
Page 12 of 17
